Summary
Eli Lilly and Company (LLY) filed an 8-K on October 24, 2017, to report its financial results for the third quarter and nine-month period ended September 30, 2017. The report primarily incorporates by reference a press release, dated October 24, 2017, which contains the detailed unaudited operating results for the specified periods. Investors should refer to this attached press release for comprehensive financial data. This filing serves as an update to the company's performance and financial condition, providing crucial information for investors to assess the company's trajectory. While the 8-K itself is brief, the attached exhibit is the primary source of information regarding revenue, earnings, and other key financial metrics for the third quarter and year-to-date 2017.
Key Highlights
- 1The 8-K filing announces the release of Eli Lilly's Q3 and nine-month 2017 financial results.
- 2The official financial results are detailed in a press release dated October 24, 2017, which is attached as Exhibit 99.1.
- 3The filing does not introduce new operational or strategic information beyond the financial results announcement.
- 4Investors are directed to the attached press release for specific financial performance data, including unaudited operating results.
- 5The report confirms Eli Lilly's adherence to reporting standards for emerging growth companies, with an option to opt-out of extended transition periods for new accounting standards.
- 6This filing is primarily informational, providing an update on the company's financial standing as of September 30, 2017.